Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery: Canadian survey

Canadian Journal of Cardiology

Volumn 30, Issue 2, 2014, Pages 231-236

  Nascimento, Thais ^a   Birnie, David H ^b   Healey, Jeff S ^c   Verma, Atul ^d   Joza, Jacqueline ^a   Bernier, Martin L ^a   Essebag, Vidal ^a,e  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d SOUTHLAKE REGIONAL HEALTH CENTRE   (Canada)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; HEART ATRIUM FIBRILLATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTATION; IMPLANTED HEART PACEMAKER; KIDNEY FUNCTION; PERIOPERATIVE PERIOD; THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; CANADA; CARDIAC SURGICAL PROCEDURES; DATA COLLECTION; DEFIBRILLATORS, IMPLANTABLE; HUMANS; INCIDENCE; PACEMAKER, ARTIFICIAL; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84893020922     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.11.027     Document Type: Article

References (23)

1. Douketis J.D., Berger P.B., Dunn A.S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008, 133:299S-339S.
2. Camm A.J., et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010, 12:1360-1420. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery.
3. Birnie D.H., Healey J.S., Wells G.A., et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013, 368:2084-2093.
4. Garcia D.A., Regan S., Henault L.E., et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch Intern Med 2008, 168:63-69.
5. Klug D., Balde M., Pavin D., et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007, 116:1349-1355.
6. Reynolds M.R., Cohen D.J., Kugelmass A.D., et al. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators. J Am Coll Cardiol 2006, 47:2493-2497.
7. Siegal D., Yudin J., Kaatz S., et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation 2012, 126:1630-1639.
8. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
9. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
10. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
11. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012, 14:1385-1413.
12. Cairns J.A., Connolly S., McMurtry S., et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
13. Skanes A.C., Healey J.S., Cairns J.A., et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012, 28:125-136.
14. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e326S-e350S.
15. Healey J.S., Brambatti M. Periprocedural management of oral anticoagulation in patients with atrial fibrillation: approach in the era of new oral anticoagulants. Can J Cardiol 2013, 29:S54-S59.
16. Bernard M.L., Shotwell M., Nietert P.J., Gold M.R. Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circ Arrhythm Electrophysiol 2012, 5:468-474.
17. Ghanbari H., Phard W.S., Al-Ameri H., et al. Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices. Am J Cardiol 2012, 110:1482-1488.
18. Rowley C.P., Bernard M.L., Brabham W.W., et al. Safety of continuous anticoagulation with dabigatran during implantation of cardiac rhythm devices. Am J Cardiol 2013, 111:1165-1168.
19. Healey J.S., Eikelboom J., Douketis J., et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation 2012, 126:343-348.
20. Mardigyan V., Verma A., Birnie D., et al. Anticoagulation management pre- and post atrial fibrillation ablation: a survey of Canadian centres. Can J Cardiol 2013, 29:219-223.
21. Lakkireddy D., Reddy Y.M., Di Biase L., et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2012, 59:1168-1174.
22. Sie P., Samama C.M., Godier A., et al. Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: thrombin or factor-Xa inhibitors. Recommendations of the Working Group on Perioperative Haemostasis and the French Study Group on Thrombosis and Haemostasis. Arch Cardiovasc Dis 2011, 104:669-676.
23. Heidbuchel H., Verhamme P., Alings M., et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013, 15:625-651.